CONy 2022 | Personalizing therapy: the future of ALS treatment

Nigel Leigh, PhD, MBBS, PhD, FRCP, FAAN, FMedSci, University of Sussex, Brighton, UK, discusses potential therapies for amyotrophic lateral sclerosis (ALS) currently in development, highlighting phenylbutyrate- taurursodiol (AMX0035) presently under trial evaluation. There is tremendous hope in developing new treatments for ALS with several ongoing clinical trials on different types of therapies such as biologicals, cell therapies, small molecules, and gene therapy. A vital question going forward is to understand how all these advances will come together for the individual treatment of patients considering the heterogeneity of the disease. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.